Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at Oppenheimer in a report issued on Friday,Benzinga reports. They presently have a $8.00 target price on the stock.
Other analysts also recently issued reports about the company. JMP Securities reiterated a "market outperform" rating and set a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Wedbush reaffirmed an "outperform" rating and set a $7.00 target price on shares of Vor Biopharma in a research note on Thursday. HC Wainwright dropped their price target on Vor Biopharma from $17.50 to $13.00 and set a "buy" rating on the stock in a research note on Friday. Finally, Stifel Nicolaus reduced their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating for the company in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma currently has an average rating of "Buy" and an average target price of $8.86.
Check Out Our Latest Analysis on Vor Biopharma
Vor Biopharma Stock Performance
Shares of NYSE VOR traded down $0.01 during midday trading on Friday, reaching $0.86. The stock had a trading volume of 181,956 shares, compared to its average volume of 590,528. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $2.43. The company's 50 day moving average price is $1.22 and its 200 day moving average price is $1.01. The firm has a market cap of $59.18 million, a price-to-earnings ratio of -0.52 and a beta of -0.40.
Institutional Trading of Vor Biopharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. RA Capital Management L.P. boosted its position in shares of Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock valued at $44,007,000 after buying an additional 16,897,159 shares during the last quarter. Lynx1 Capital Management LP bought a new position in Vor Biopharma during the 4th quarter valued at $707,000. Trustees of Columbia University in the City of New York bought a new position in Vor Biopharma during the 4th quarter valued at $102,000. XTX Topco Ltd bought a new stake in shares of Vor Biopharma in the 4th quarter worth $80,000. Finally, Virtu Financial LLC purchased a new stake in shares of Vor Biopharma in the fourth quarter valued at about $60,000. 97.29% of the stock is owned by institutional investors.
Vor Biopharma Company Profile
(
Get Free Report)
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Further Reading
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
